Pharmaceuticals
-
IFC Supports B. Braun Melsungen`s local pharmaceuticals manufacturing in Indonesia
Jul 13, 2016News Hour: IFC, a member of the World Bank Group, will provide a loan equal to 450 billion Indonesian Rupiah (approximately 33 million US Dollars) to B. Braun Melsungen AG operations in Indonesia to help finance... -
Blood test to help prevent unwarranted prescribing of antibiotics
Jul 7, 2016News Hour: An inexpensive blood test could one day tell doctors whether an infection is caused by a virus or a bacteria, and help prevent unwarranted prescribing of antibiotics, researchers said on Wednesday, reports BSS. The... -
GSK announces start of phase I oncology study with ICOS agonist antibody
Jun 30, 2016News Hour: GSK today announced the start of a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costimulator (ICOS) agonist antibody. ICOS is a co-stimulatory receptor that enhances T-cell responses and results in an... -
Phase III study shows Roche’s Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA)
Jun 29, 2016News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive results from the Phase III study known as GiACTA, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). The study met its primary and... -
Roche’s Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Jun 29, 2016News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or... -
Roche employees raise funds for vulnerable children in over 90 communities around the world
Jun 29, 2016News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) employees in 70 countries and 141 sites come together to participate in the 2016 Roche Children’s Walk, which takes place on the International Day of the African Child.... -
The new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing
Jun 29, 2016News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark. As diagnostic laboratories evolve to... -
Roche’s marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Jun 29, 2016News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of OCREVUS® (ocrelizumab) for the treatment of relapsing multiple sclerosis (RMS) and primary... -
Promising data from next generation alk/ros1 inhibitor in advanced non-small cell lung cancer
Jun 29, 2016News Hour: Pfizer Inc. (NYSE:PFE) announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients... -
Data from phase 1b trial investigating utomilumab (a 4-1bb agonist) in combination with a checkpoint inhibitor
Jun 29, 2016News Hour: Pfizer Inc. (NYSE:PFE) announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab (the proposed non-proprietary name for PF-05082566), a 4-1BB (also called CD137) agonist, in combination with pembrolizumab, a PD-1...
